Showing 1‐15 of 15
Webinar (on-demand)
50 min read
Enhanced GS® CHO Vector Technology for Improved Expression Control of Biotherapeutic Proteins
Many of today’s expression platforms for recombinant protein production have been optimised for the expression of monoclonal antibodies, often with the platform fundamentals originating from the 1990s. However, as new modalities increase in prevalence, pa...
e-book
15 min read
Experts in Expression: Recent Advances in CHO Upstream Bioproduction
Constantly evolving biopharmaceutical pipelines require continuous evolution of CHO-based bioproduction platforms for discovery, development and commercial applications. Cell lines must more efficiently and consistently deliver high yields of diverse and ...
Article
10 min read
Creating Next-Generation CHO Expression Platforms Through Application of Omics Technologies
Chinese hamster ovary (CHO)-based biomanufacturing platforms have transformed the industrial production of biologics such as monoclonal antibodies (mAbs) over the last few decades, and despite advances in alternative expression systems (E. coli, yeast, et...
Article
10 min read
The Crucial Role of GS-CHO Innovation in Biopharmaceutical Progress
With a long standing track record of success, GS-CHO based expression systems have become the most widely used platform for developing and manufacturing recombinant therapeutic proteins today. But the evolving demands of the biologics industry including p...
Podcast
39 min read
CHO Talks: A Deep Dive into Expression Approaches for Biotherapeutics
What are the considerations to make when selecting a CHO expression format to produce your biotherapeutics? Whether you’re at the discovery stage or thinking about commercial production, our experts, with decades of experience in the field, provide useful...
Interview
9 min read
Q&A: Why Use GS piggyBac® Transposase Technology for Expression of Your Biotherapeutics?
Webinar (on-demand)
33 min read
Creating Next-Generation GS-CHO Expression Solutions
Over the last 30 years, optimization of CHO biotherapeutic expression systems and processes has realized dramatic advances in key performance attributes such as titers. By leveraging high throughput systems for clone generation and screening, the chances ...
Poster
3 min read
GS Discovery® System for High Titer Transient Expression
GS Discovery® is a novel, scalable, transient expression solution driving high titers that rival those of leading off-the-shelf kits. As part of the GS System®, GS Discovery® enables you to use the same tools (cell lines, vectors and GS piggyBac® transpos...
Article
20 min read
Strategies to Optimize Expression Challenges of Multi-chain and Bispecific Antibodies
Many of today's expression platforms for recombinant protein manufacturing have been optimised for the expression of monoclonal antibodies (mAbs), often with the platform fundamentals originating from the 1990's. However, as new modalities increase in pre...
Webinar (on-demand)
20 min read
GS Discovery® – Taking A Hybrid Approach For Optimizing Transient Protein Expression In CHO Cells
In this presentation, Peter O’Callaghan discusses how Lonza's optimized transient expression workflow combines the benefits of transient protein expression and the construction of stable pools. Our novel ‘hybrid’ process, part of our GS Discovery® offerin...
White paper
7 min read
Optimization of Transient Protein Expression in CHO Cells
Recombinant therapeutic protein expression using mammalian platforms can be achieved using a range of workflows optimized for different objectives. These processes include transient transfection, and the creation of stable pools and clonal cell lines. Tr...
Presentation (on-demand)
14 min read
bYlok® Technology: Precision Execution of Bispecifics
Bispecific antibodies offer advantages as therapeutic modalities, including precise targeting and increased efficacy. However, production in CHO cells can present challenges that affect COGs, such as incorrect antibody chain pairing. In this presentation ...
Presentation (on-demand)
13 min read
Taking a Hybrid Approach For Optimizing Transient Protein Expression In CHO Cells
When choosing between protein expression formats such as transient versus stable pools, considerations include speed, titre, and product quality. In this presentation we will show how we have optimised the transient expression workflow for the GS Xceed® C...
Webinar (on-demand)
bYlok® Technology: Our Solution for Improved Design and Production of Bispecific Therapeutics
As the market for bispecific antibody therapeutics continues to soar, novel solutions are required to overcome challenges in producing these next-generation molecules. In this presentation, our expert demonstrates how bYlok® uses a close-to-nature des...
Webinar (on-demand)
37 min read
Meet Challenges in Expressing Next-Gen Immunotherapies and Other Advanced Biologics
Biological pipelines are evolving from standard antibody formats to next-generation biologics. These advances increase pressure on cell line construction timelines and create challenges in identifying cell lines that meet production needs. As a result, hi...